MedPath

Nxera Pharma Partners with Holling Bio-Pharma to Launch Daridorexant for Insomnia in Taiwan

• Nxera Pharma has established a strategic partnership with Holling Bio-Pharma, Taiwan's largest pharmaceutical distributor, to commercialize daridorexant for insomnia treatment in the Taiwanese market.

• The agreement addresses a significant medical need in Taiwan, where sleep disorders affect 12-20% of the adult population, approximately 4-5 million people as of 2021.

• Holling Bio-Pharma brings nearly five decades of experience in drug distribution and extensive expertise in CNS products, positioning the partnership for successful market penetration.

Nxera Pharma has announced a strategic commercialization agreement with Holling Bio-Pharma Corp. to bring daridorexant, a novel insomnia treatment, to the Taiwanese market. The partnership combines Nxera's innovative therapeutic development with Holling's established presence as Taiwan's largest pharmaceutical distributor.

Addressing a Critical Healthcare Need

The collaboration targets a significant medical challenge in Taiwan, where insomnia disorder affects between 12-20% of the adult population, translating to approximately 4-5 million individuals, according to Taiwan's National Health Research Institutes. Insomnia disorder, characterized by persistent difficulties in initiating or maintaining sleep, significantly impacts patients' daytime functioning and overall quality of life.

Understanding Insomnia's Impact

Insomnia disorder extends beyond occasional sleep difficulties, representing a persistent condition that affects both physical and mental health. Research demonstrates that patients with insomnia maintain higher levels of wake-signaling brain activity during sleep periods, distinguishing it from temporary sleep disturbances. The condition can severely impact concentration, mood, and energy levels, necessitating targeted therapeutic intervention.

Strategic Partnership Dynamics

Holling Bio-Pharma brings nearly five decades of pharmaceutical distribution experience to the partnership. The company has established a robust track record in handling innovative products, including small molecule drugs, biologics, and vaccines. Their expertise specifically in the CNS field, with successful launches of innovative products from both EU and US markets, positions them ideally for this collaboration.

Treatment Approach and Market Potential

Current insomnia treatment protocols encompass sleep hygiene therapy, cognitive behavioral therapy, and pharmacotherapy. The introduction of daridorexant aims to enhance the treatment landscape by improving both sleep quality and quantity while minimizing adverse events and next-morning residual effects.

About the Partners

Nxera Pharma operates as a technology-powered biopharma company with a global presence, employing over 350 professionals across key locations in Tokyo, Osaka, London, Cambridge, Basel, and Seoul. The company maintains an extensive pipeline of over 30 active programs, leveraging its proprietary GPCR-targeted structure-based drug discovery platform, NxWave™.
Holling Bio-Pharma, headquartered in Taipei, offers comprehensive services including drug registration, market access, product promotion, warehousing, and logistics. Their established infrastructure and expertise in the Taiwanese pharmaceutical market provide a strong foundation for the successful commercialization of daridorexant.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Issues Refusal to File for Pitolisant in Idiopathic Hypersomnia Treatment

Harmony Biosciences receives FDA Refusal to File letter for pitolisant's supplemental New Drug Application in adult idiopathic hypersomnia patients with excessive daytime sleepiness.
Phase 3 INTUNE study failed to meet primary endpoint for statistical significance, despite showing clinically meaningful improvements in patient wakefulness during open-label phase.

Corcept Therapeutics Submits New Drug Application for Relacorilant to Treat Cushing's Syndrome

Corcept Therapeutics has submitted a New Drug Application to the FDA for relacorilant, a selective cortisol modulator designed to treat patients with endogenous hypercortisolism (Cushing's syndrome).
The application is supported by positive results from multiple clinical trials, including the pivotal GRACE trial, Phase 3 GRADIENT study, and long-term extension studies, demonstrating improvements in various symptoms with an acceptable safety profile.

IDEAYA Biosciences Licenses DLL3-Targeting ADC from Hengrui Pharma in $1B Deal

IDEAYA Biosciences has secured an exclusive license from Hengrui Pharma for SHR-4849, a DLL3-targeting antibody-drug conjugate (ADC), outside of Greater China.
SHR-4849 is currently in Phase 1 trials and has demonstrated promising antitumor activity in preclinical studies, particularly in small cell lung cancer (SCLC).

Nxera Pharma Initiates Phase 3 Trial of Daridorexant for Insomnia in South Korea

Nxera Pharma has enrolled the first patient in a Phase 3 clinical trial in South Korea to evaluate daridorexant for treating insomnia.
The trial aims to secure marketing authorization from South Korea's Ministry of Food and Drug Safety, with results expected in 1H 2026.

Tonix Pharmaceuticals' TNX-102 SL Shows Promise in Fibromyalgia Treatment

Tonix Pharmaceuticals presented Phase 3 RESILIENT study data, revealing TNX-102 SL significantly reduced fibromyalgia pain versus placebo.
The study met all six key secondary endpoints, including improved sleep quality, reduced fatigue, and enhanced overall function in patients.

Tonix Pharmaceuticals' TNX-102 SL Awaits FDA Decision for Fibromyalgia Treatment

Tonix Pharmaceuticals' TNX-102 SL, a non-opioid analgesic, has been assigned an FDA PDUFA goal date of August 15, 2025, for fibromyalgia treatment, potentially offering a new option for millions.
TNX-102 SL demonstrated significant pain reduction and improved sleep quality in Phase 3 trials, addressing key fibromyalgia symptoms with a well-tolerated safety profile.

Tonix Pharmaceuticals Seeks FDA Approval for TNX-102 SL in Fibromyalgia

Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for TNX-102 SL, targeting sleep and pain relief in fibromyalgia patients.
Phase 3 trials demonstrated that TNX-102 SL significantly reduced daily pain and improved sleep quality compared to placebo in fibromyalgia patients.

Magnetic Pulses Show Promise in Treating Chronic Insomnia

Researchers are developing a handheld device that uses magnetic pulses to treat chronic insomnia by targeting the default mode network (DMN).
A $3 million grant from the Department of Defense is funding a study at the University of Arizona focusing on military personnel affected by sleeplessness.

Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan Following Approval for Insomnia

Nxera Pharma has entered a commercial partnership with Shionogi for the distribution and sales of Quviviq in Japan, succeeding a prior agreement with Mochida Pharmaceutical.
Quviviq, a dual orexin receptor antagonist, received approval in Japan for treating adult insomnia, marking a significant advancement in addressing sleep disorders.

Centessa's ORX750 Advances to Phase 2 for Narcolepsy and Idiopathic Hypersomnia After Promising Phase 1 Results

Centessa Pharmaceuticals' ORX750, an orexin receptor 2 (OX2R) agonist, demonstrated significant improvements in wakefulness in sleep-deprived healthy volunteers.
The 2.5 mg dose of ORX750 restored normal wakefulness, achieving a mean sleep latency of 32 minutes compared to 17 minutes with placebo.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy